Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Osteogenesis imperfecta (OI) is an inherited skeletal disorder that leads to bone fragility and multiple fractures. Given advances in the genetic understanding of existing phenotypes and newly discovered mutations, therapeutic management of OI has become challenging. Denosumab, a monoclonal antibody that inhibits the interaction between the receptor activator of nuclear factor kappa B ligand (RANKL) and its receptor RANK, has been approved to treat postmenopausal osteoporosis and emerged as an important therapy for malignancies and other skeletal disorders, including pediatric skeletal conditions such as OI. This review summarizes information about denosumab therapy in OI by exploring its mechanisms of action, main indications, and safety and efficacy. Several case reports and small series have been published about the short-term use of denosumab in children with OI. Denosumab was considered a strong drug candidate for OI patients with bone fragility and a high risk of fracture, particularly for patients with the bisphosphonate (BP)-unresponsive OI-VI subtype. The evidence for denosumab's effects in children with OI indicates that it effectively improves bone mineral density but not fracture rates. A decrease in bone resorption markers was observed after each treatment. Safety was assessed by tracking the effects on calcium homeostasis and reporting side effects. No severe adverse effects were reported. Hypercalciuria and moderate hypercalcemia were reported, suggesting that BPs be used to prevent the bone rebound effect. In other words, denosumab can be used as a targeted intervention in children with OI. The posology and administration protocol require more investigation to achieve secure efficiency.
Abstract
Osteogenesis imperfecta (OI) is an inherited skeletal disorder that leads to bone fragility and multiple fractures. Given advances in the genetic understanding of existing phenotypes and newly discovered mutations, therapeutic management of OI has become challenging. Denosumab, a monoclonal antibody that inhibits the interaction between the receptor activator of nuclear factor kappa B ligand (RANKL) and its receptor RANK, has been approved to treat postmenopausal osteoporosis and emerged as an important therapy for malignancies and other skeletal disorders, including pediatric skeletal conditions such as OI. This review summarizes information about denosumab therapy in OI by exploring its mechanisms of action, main indications, and safety and efficacy. Several case reports and small series have been published about the short-term use of denosumab in children with OI. Denosumab was considered a strong drug candidate for OI patients with bone fragility and a high risk of fracture, particularly for patients with the bisphosphonate (BP)-unresponsive OI-VI subtype. The evidence for denosumab's effects in children with OI indicates that it effectively improves bone mineral density but not fracture rates. A decrease in bone resorption markers was observed after each treatment. Safety was assessed by tracking the effects on calcium homeostasis and reporting side effects. No severe adverse effects were reported. Hypercalciuria and moderate hypercalcemia were reported, suggesting that BPs be used to prevent the bone rebound effect. In other words, denosumab can be used as a targeted intervention in children with OI. The posology and administration protocol require more investigation to achieve secure efficiency.
참고문헌 (54)
- Tournis S, "Osteogenesis imperfecta-A clinical update", Metabolism, 80, pp.27~37 (2018)
- Claeys L, "Collagen transport and related pathways in Osteogenesis Imperfecta", Hum Genet, 140, pp.1121~1141 (2021)
- Zaripova AR, "Modern classification and molecular-genetic aspects of osteogenesis imperfecta", Vavilov J Genet Breed, 24, pp.219~227 (2020)
- Mortier GR, "Nosology and classification of genetic skeletal disorders : 2019 revision", Am J Med Genet A, 179, pp.2393~2419 (2019)
- Marom R, "Osteogenesis imperfecta : an update on clinical features and therapies", Eur J Endocrinol, 183, pp.R95~R106 (2020)
- Rossi V, "Osteogenesis imperfecta : advancements in genetics and treatment", Curr Opin Pediatr, 31, pp.708~715 (2019)
- Ralston SH, "Management of osteogenesis imperfecta", Front Endocrinol, 10, pp.924~ (2019)
- Dwan K, "Bisphosphonate therapy for osteogenesis imperfecta", Cochrane Database Syst Rev, 10, pp.CD005088~ (2016)
- Yoon RS, "Long-term bisphosphonate usage and subtrochanteric insufficiency fractures : a cause for concern?", J Bone Joint Surg Br, 93, pp.1289~1295 (2011)
- Lewiecki EM, "Clinical use of denosumab for the treatment for postmenopausal osteoporosis", Curr Med Res Opin, 26, pp.2807~2812 (2010)
- Boyce AM, "Denosumab : an emerging therapy in pediatric bone disorders", Curr Osteoporos Rep, 15, pp.283~292 (2017)
- Stefano Stagi, "Bone modeling, remodeling, and skeletal health in children and adolescents: mineral accrual, assessment and treatment", Annals of Pediatric Endocrinology & Metabolism, 22(1), pp.1~5 (2017), 대한소아내분비학회[DOI]
- Gosman JH, "Skeletal biology over the life span : a view from the surfaces", Am J Phys Anthropol, 146(Suppl 53), pp.86~98 (2011)
- Florencio-Silva R, "Biology of bone tissue : structure, function, and factors that influence bone cells", BioMed Res Int, 2015, pp.421746~ (2015)
- El-Gazzar A, "Mechanisms of bone fragility : from osteogenesis imperfecta to secondary osteoporosis", Int J Mol Sci, 22, pp.625~ (2021)
- Rauch F, "Static and dynamic bone histomorphometry in children with osteogenesis imperfecta", Bone, 26, pp.581~589 (2000)
- Braga V, "Bone turnover markers in patients with osteogenesis imperfecta", Bone, 34, pp.1013~1016 (2004)
- Glorieux FH, "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta", N Engl J Med, 339, pp.947~952 (1998)
- Semler O, "Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta", Horm Res Paediatr, 76, pp.321~327 (2011)
- Land C, "Osteogenesis imperfecta type VI in childhood and adolescence : effects of cyclical intravenous pamidronate treatment", Bone, 40, pp.638~644 (2007)
- Uehara M, "Efficacy of denosumab for osteoporosis in three female patients with osteogenesis imperfecta", Tohoku J Exp Med, 242, pp.115~120 (2017)
- Whyte MP, "Bisphosphonate-induced osteopetrosis", N Engl J Med, 349, pp.457~463 (2003)
- Thompson RN, "Atypical femoral fractures and bisphosphonate treatment : experience in two large United Kingdom teaching hospitals", J Bone Joint Surg Br, 94, pp.385~390 (2012)
- Boyde A, "The mineralization density of iliac crest bone from children with osteogenesis imperfecta", Calcif Tissue Int, 64, pp.185~190 (1999)
- Fratzl-Zelman N, "CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII", Bone, 46, pp.820~826 (2010)
- Fratzl-Zelman N, "Bone mass and mineralization in osteogenesis imperfecta", Wien Med Wochenschr, 165, pp.271~277 (2015)
- Lacey DL, "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", Cell, 93, pp.165~176 (1998)
- Hsu H, "Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand", Proc Natl Acad Sci U S A, 96, pp.3540~3545 (1999)
- Simonet WS, "Osteoprotegerin : a novel secreted protein involved in the regulation of bone density", Cell, 89, pp.309~319 (1997)
- Hofbauer LC, "Clinical implications of the osteoprotegerin", RANKL, JAMA, pp.2004, 292[DOI]
- Ominsky MS, "Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab", J Bone Miner Res Off J Am Soc Bone Miner Res, 30, pp.1280~1289 (2015)
- Kendler DL, "Denosumab in the treatment of osteoporosis : 10 years later : a narrative review", Adv Ther, 39, pp.58~74 (2022)
- Deeks ED, "Denosumab : a review in postmenopausal osteoporosis", Drugs Aging, 35, pp.163~173 (2018)
- Bone HG, "10 years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5, pp.513~523 (2017)
- Grasemann C, "Effects of RANK-ligand antibody(denosumab)treatment on bone turnover markers in a girl with juvenile Paget’s disease", J Clin Endocrinol Metab, 98, pp.3121~3126 (2013)
- Boyce AM, "Denosumab treatment for fibrous dysplasia", J Bone Miner Res Off J Am Soc Bone Miner Res, 27, pp.1462~1470 (2012)
- Naidu A, "Management of central giant cell granuloma with subcutaneous denosumab therapy", J Oral Maxillofac Surg, 72, pp.2469~2484 (2014)
- Chawla S, "Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone : interim analysis of an open-label, parallel-group, phase 2 study", Lancet Oncol, 14, pp.901~908 (2013)
- Lange T, "Denosumab : a potential new and innovative treatment option for aneurysmal bone cysts", Eur Spine J, 22, pp.1417~1422 (2013)
- Ciancia S, "Osteoporosis in children and adolescents : when to suspect and how to diagnose it", Eur J Pediatr, 181, pp.2549~2561 (2022)
- Hoyer-Kuhn H, "Two years’ experience with denosumab for children with osteogenesis imperfecta type VI", Orphanet J Rare Dis, 9, pp.145~ (2014)
- Hoyer-Kuhn H, "Effect of denosumab on the growing skeleton in osteogenesis imperfecta", J Clin Endocrinol Metab, 99, pp.3954~3955 (2014)
- Hoyer-Kuhn H, "Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial", J Musculoskelet Neuronal Interact, 16, pp.24~32 (2016)
- Hoyer-Kuhn H, "Individualized treatment with denosumab in children with osteogenesis imperfecta-follow up of a trial cohort", Orphanet J Rare Dis, 14, pp.219~ (2019)
- Trejo P, "Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI", J Musculoskelet Neuronal Interact, 18, pp.76~80 (2018)
- Ward L, "Osteogenesis Imperfecta Type VI in Individuals from Northern Canada", Calcif Tissue Int, 98, pp.566~572 (2016)
- Semler O, "First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI", J Musculoskelet Neuronal Interact, 12, pp.183~188 (2012)
- Glorieux FH, "Osteogenesis imperfecta type VI : a form of brittle bone disease with a mineralization defect", J Bone Miner Res, 17, pp.30~38 (2002)
- Rauch F, "Osteogenesis imperfecta", Lancet Lond Engl, 363, pp.1377~1385 (2004)
- Zheng S, "Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting targetmediated drug disposition", CPT Pharmacomet Syst Pharmacol, 3, pp.e138~ (2014)
- Sutjandra L, "Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis", Clin Pharmacokinet, 50, pp.793~807 (2011)
- Li G, "Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings", Acta Paediatr, 107, pp.534~537 (2018)
- Wang HD, "Effects of denosumab treatment and discontinuation on human growth plates", J Clin Endocrinol Metab, 99, pp.891~897 (2014)
- Cintas HL, "Brief assessment of motor function : reliability and concurrent validity of the Gross Motor Scale", Am J Phys Med Rehabil, 82, pp.33~41 (2003)